Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305405 · ClinicalTrials.gov registry record · Phase 3
PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT04305405 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT04305405, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will evaluate the PK, PD and long-term safety of Benralizumab administered subcutaneously in 30 children aged 6 to 11 years with severe eosinophilic asthma. Up to an additional 3 Japanese patients aged 12 to 14 years will be enrolled to meet local regulatory requirements.
Interventions
- DRUG Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-11-21 |
| Est. Completion | 2022-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04305405
The ClinicalTrials.gov registry entry for NCT04305405 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Benralizumab is the first listed.
NCT04305405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04305405 about?
NCT04305405 is a clinical study titled "PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma". This study will evaluate the PK, PD and long-term safety of Benralizumab administered subcutaneously in 30 children aged 6 to 11 years with severe eosinophilic asthma. Up to an additional 3 Japanese patients aged 12 to 14 years will be enrolled to meet local regulatory requirements.
What is the current status of trial NCT04305405?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2019-11-21. Estimated completion is 2022-09-12.
What interventions are being tested in trial NCT04305405?
The interventions under investigation include: Benralizumab (DRUG).
Who is sponsoring clinical trial NCT04305405?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.